Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the Third Annual Next-Gen Immuno-oncology Congress occurring virtually June 25-26, 2020.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they have entered a two-year strategic partnership with
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they have been awarded a grant for the development of a software platform called Antibody Drug Conjugate (ADC) Workbench to facilitate efficient knowledge discovery and enable rapid knowledge qualificati
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that it is creating a systems pharmacology model to support ongoing research into the compassionate care use of tissue plasminogen activator (tPA) as treatment of respiratory distress for patients with A
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced the continuation of their collaboration with Zymeworks Inc. Applied BioMath will design and deliver a systems pharmacology model for a therapeutic platform Zymeworks has in development.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xilio Therapeutics.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Northern Biologics for semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of Northern Biologics' lead preclinical antibody for the treatment of cancer. Northern Biologics will leverage Applied Biomath's modelling expertise to strengthen their understanding of key biological a
Applied BioMath, LLC, the industry leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with OncoMyx Therapeutics, a priv
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their upcoming webinar, "Translational Modeling Strategies to Predict Clinical Doses for CD3 Bispecific Molecules'' occurs Thursday, March 12, 2020 at 2p.m. ET / 11a.m. PT.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the Festival of Biologics occurring March 2-4, 2020 in San Diego, CA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Gritstone Oncology, Inc. for semi-mechanistic systems pharmacology modeling. Applied BioMath created a semi-mechanistic pharmacokinetic, receptor occupancy model for a Gritstone Oncology, Inc.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their upcoming webinar, "Model-Based Approach to Design Bispecific Modalities in Early Discovery" occurs Tuesday, February 4, 2020 at 2p.m. ET / 11a.m. PT.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their fourth annual Quantitative Systems Pharmacology (QSP) Summit will occur May 20-21, 2020 at the MIT Samberg Conference Center in Cambridge, MA.
Helen Moore has been appointed Council at Society for Industrial and Applied Mathematics (SIAM).
Helen Moore, Director of Applied Mathematics at Applied BioMath, will use her position to proactively address challenges including decisions that need to be made about ethics issues, open access journal policies, declining journal subscriptions, and emerging platforms for communicating research results. Moore currently serves on SIAM's Council.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at The Society for Immunotherapy of Cancer (SITC) occurring November 6th-10th in National Harbor, Maryland. They will present two posters at the conference Friday, November 8th.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at PharmSci 360 occurring November 3-6, 2019 in San Antonio, Texas.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development,
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they will host Quantitative Systems Pharmacology (QSP) Day November 12, 2019 from 2-7p.m. at the AC Hotel by Marriott San Francisco Airport/Oyster Point Waterfront in South San Francisco, CA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, is proud to welcome Joshuaine Grant as Senior Principal Scientist.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation in the following five sessions at ACoP10 occurring October 20-24, 2019 in Orlando, FL.
Monday, October 21st
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, is proud to welcome Kas Subramanian, PhD as Senior Director of Preclinical Modeling.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the World Bispecific Summit occurring September 17-19, 2019 in Waltham, MA. John Burke, PhD, Co-Founder, President and CEO, Applied BioMath is chairing a session titled "Pioneering
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced an agreement with Verseau Therapeutics for the delivery of systems pharmacology pharmacokinetic and target engagement analysis to provide early feasibility assessments for the treatment of cancer.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at the Immuno-Oncology Summit occurring August 5-9, 2019 in Boston, MA. John Burke, PhD, Co-Founder, President and CEO, Applied BioMath will present "Model Aided
Applied BioMath (www.appliedbiomath.com), the industry leader in applying systems and mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, is proud to welcome Alison Betts, as Senior Director of Scientific Collaborations and Fellow of Modeling & Simulation.